文献速递炎症性肠病

临床疾病活动度、生化活动度与心理健康在8年纵向随访中对炎症性肠病自然史的累积影响

Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up.
PubMed 文献 · Aliment Pharmacol Ther · 2025-03-09

该纵向随访研究纳入有临床活动度数据的717例和有临床及生化活动度数据的187例炎症性肠病患者,按疾病活动度及基线常见精神障碍症状分组,随访8.1年,用Cox回归比较不良结局。结果显示心理共病与疾病活动度对不良结局有累积影响,心理共病和活动性疾病对IBD预后有累积不良影响。

要点

  • 临床活动度合并两种常见精神障碍时,不良结局发生率更高。
  • 临床与生化活动度合并两种常见精神障碍时,住院或肠切除风险更高。
  • 心理共病与活动性疾病对IBD预后有累积不良影响。

核心结论

  • 心理共病和活动性疾病对炎症性肠病预后有累积不良影响。

研究设计与样本

  • 纵向随访研究,收集基线人口学和炎症性肠病相关信息,使用疾病活动度评分评估临床活动度、使用钙卫蛋白评估生化活动度,按疾病活动度有无分组,再按基线常见精神障碍症状有无亚组分析,随访8.1年,用Cox回归比较亚组间不良结局发生情况。
  • 有临床活动度数据的参与者717例,有临床和生化活动度数据的参与者187例。

主要发现

  • 临床活动度组中,发作或糖皮质激素处方风险 HR 2.89(95% CI 1.68-4.93),升级治疗或死亡风险 HR 2.52(95% CI 1.55-4.10),另一不良结局风险 HR 6.97(95% CI 2.43-20.0)。
  • 临床和生化活动度组中,发作或糖皮质激素处方风险 HR 7.26(95% CI 2.86-18.5),升级治疗或死亡风险 HR 3.62(95% CI 1.59-8.25),另一不良结局风险 HR 57.3(95% CI 7.58-433)。
  • 临床和生化活动度合并两种常见精神障碍时,住院风险 HR 6.20(95% CI 1.88-20.4),住院和/或肠切除风险 HR 7.46(95% CI 2.41-23.2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Common mental disorders, including anxiety and depression, are prevalent in patients with inflammatory bowel disease (IBD) and may be associated with adverse outcomes. However, whether increasing psychological co-morbidity, in combination with disease activity, exerts a cumulative effect on prognosis is uncertain. AIMS: To assess this in a longitudinal follow-up study. METHODS: We collected baseline demographic and IBD-related information, clinical activity using disease activity scores and biochemical activity using calprotectin. Patients were grouped according to the presence or absence of disease activity. Patients in remission or with active disease were subgrouped according to the presence or absence of symptoms of a common mental disorder at baseline. We recorded the occurrence of adverse outcomes over 8.1 years, comparing their occurrence across subgroups using Cox regression. RESULTS: Among 717 participants with clinical activity data and 187 with clinical and biochemical activity data, rates of adverse outcomes increased with both disease activity and increasing psychological co-morbidity. Rates of flare or glucocorticosteroid prescription, escalation or death were higher with clinical activity (HR 2.89; 95% CI 1.68-4.93 and 2.52; 95% CI 1.55-4.10 and 6.97; 95% CI 2.43-20.0, respectively) or clinical and biochemical activity (HR 7.26; 95% CI 2.86-18.5, 3.62; 95% CI 1.59-8.25 and 57.3; 95% CI 7.58-433, respectively) and two common mental disorders. Rates of hospitalisation (HR 6.20; 95% CI 1.88-20.4) or hospitalisation and/or intestinal resection (HR 7.46; 95% CI 2.41-23.2) were higher with clinical and biochemical activity and two common mental disorders. CONCLUSION: Psychological co-morbidity and active disease have a cumulative adverse impact on IBD prognosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Riggott C, Fairbrass KM, Gracie DJ, et al. Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up. Aliment Pharmacol Ther. 2025. PMID: 40057941. doi:10.1111/apt.70068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。